Tailoring FXR Modulators for Intestinal Specificity: Recent Progress and Insights

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2024 May 11

PMID 38731514

Authors

Amanda Morrison

Bahaa Elgendy

Affiliations

Soon will be listed here.

Abstract

While FXR has shown promise in regulating bile acid synthesis and maintaining glucose and lipid homeostasis, undesired side effects have been observed in clinical trials. To address this issue, the development of intestinally restricted FXR modulators has gained attention as a new avenue for drug design with the potential for safer systematic effects. Our review examines all currently known intestinally restricted FXR ligands and provides insights into the steps taken to enhance intestinal selectivity.

References

Hollman D, Milona A, van Erpecum K, van Mil S . Anti-inflammatory and metabolic actions of FXR: insights into molecular mechanisms. Biochim Biophys Acta. 2012; 1821(11):1443-52. DOI: 10.1016/j.bbalip.2012.07.004. View

Ren Q, Chen Y, Zhou Z, Cai Z, Jiao S, Huang W . Discovery of the First-in-Class Intestinal Restricted FXR and FABP1 Dual Modulator ZLY28 for the Treatment of Nonalcoholic Fatty Liver Disease. J Med Chem. 2023; 66(9):6082-6104. DOI: 10.1021/acs.jmedchem.2c01918. View

Zhang Y, Lee F, Barrera G, Lee H, Vales C, Gonzalez F . Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci U S A. 2006; 103(4):1006-11. PMC: 1347977. DOI: 10.1073/pnas.0506982103. View

Sun L, Xie C, Wang G, Wu Y, Wu Q, Wang X . Gut microbiota and intestinal FXR mediate the clinical benefits of metformin. Nat Med. 2018; 24(12):1919-1929. PMC: 6479226. DOI: 10.1038/s41591-018-0222-4. View

Winiwarter S, Ax F, Lennernas H, Hallberg A, Pettersson C, Karlen A . Hydrogen bonding descriptors in the prediction of human in vivo intestinal permeability. J Mol Graph Model. 2002; 21(4):273-87. DOI: 10.1016/s1093-3263(02)00163-8. View

Xie C, Jiang C, Shi J, Gao X, Sun D, Sun L . An Intestinal Farnesoid X Receptor-Ceramide Signaling Axis Modulates Hepatic Gluconeogenesis in Mice. Diabetes. 2017; 66(3):613-626. PMC: 5319721. DOI: 10.2337/db16-0663. View

Downes M, Verdecia M, Roecker A, Hughes R, Hogenesch J, Kast-Woelbern H . A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR. Mol Cell. 2003; 11(4):1079-92. PMC: 6179153. DOI: 10.1016/s1097-2765(03)00104-7. View

Teno N, Yamashita Y, Masuda A, Iguchi Y, Oda K, Fujimori K . Identification of potent farnesoid X receptor (FXR) antagonist showing favorable PK profile and distribution toward target tissues: Comprehensive understanding of structure-activity relationship of FXR antagonists. Bioorg Med Chem. 2019; 27(11):2220-2227. DOI: 10.1016/j.bmc.2019.04.029. View

Mo C, Xu X, Zhang P, Peng Y, Zhao X, Chen S . Discovery of HPG1860, a Structurally Novel Nonbile Acid FXR Agonist Currently in Clinical Development for the Treatment of Nonalcoholic Steatohepatitis. J Med Chem. 2023; 66(14):9363-9375. DOI: 10.1021/acs.jmedchem.3c00456. View

10.

Xie Z, Jiang H, Liu W, Zhang X, Chen D, Sun S . The triterpenoid sapogenin (2α-OH-Protopanoxadiol) ameliorates metabolic syndrome via the intestinal FXR/GLP-1 axis through gut microbiota remodelling. Cell Death Dis. 2020; 11(9):770. PMC: 7499306. DOI: 10.1038/s41419-020-02974-0. View

11.

Zhang C, Liu Y, Wang Y, Ge X, Jiao T, Yin J . Discovery of Betulinic Acid Derivatives as Potent Intestinal Farnesoid X Receptor Antagonists to Ameliorate Nonalcoholic Steatohepatitis. J Med Chem. 2022; 65(19):13452-13472. DOI: 10.1021/acs.jmedchem.2c01394. View

12.

Maran R, Thomas A, Roth M, Sheng Z, Esterly N, Pinson D . Farnesoid X receptor deficiency in mice leads to increased intestinal epithelial cell proliferation and tumor development. J Pharmacol Exp Ther. 2008; 328(2):469-77. PMC: 2682273. DOI: 10.1124/jpet.108.145409. View

13.

Huang W, Cao Z, Wang W, Yang Z, Jiao S, Chen Y . Discovery of LH10, a novel fexaramine-based FXR agonist for the treatment of liver disease. Bioorg Chem. 2024; 143:107071. DOI: 10.1016/j.bioorg.2023.107071. View

14.

Landrier J, Eloranta J, Vavricka S, Kullak-Ublick G . The nuclear receptor for bile acids, FXR, transactivates human organic solute transporter-alpha and -beta genes. Am J Physiol Gastrointest Liver Physiol. 2005; 290(3):G476-85. DOI: 10.1152/ajpgi.00430.2005. View

15.

Yin Y, Wang M, Gu W, Chen L . Intestine-specific FXR agonists as potential therapeutic agents for colorectal cancer. Biochem Pharmacol. 2021; 186:114430. DOI: 10.1016/j.bcp.2021.114430. View

16.

Massafra V, Pellicciari R, Gioiello A, van Mil S . Progress and challenges of selective Farnesoid X Receptor modulation. Pharmacol Ther. 2018; 191:162-177. DOI: 10.1016/j.pharmthera.2018.06.009. View

17.

Fang Y, Hegazy L, Finck B, Elgendy B . Recent Advances in the Medicinal Chemistry of Farnesoid X Receptor. J Med Chem. 2021; 64(24):17545-17571. DOI: 10.1021/acs.jmedchem.1c01017. View

18.

Ma K, Saha P, Chan L, Moore D . Farnesoid X receptor is essential for normal glucose homeostasis. J Clin Invest. 2006; 116(4):1102-9. PMC: 1409738. DOI: 10.1172/JCI25604. View

19.

Pellicciari R, Passeri D, De Franco F, Mostarda S, Filipponi P, Colliva C . Discovery of 3α,7α,11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid (TC-100), a Novel Bile Acid as Potent and Highly Selective FXR Agonist for Enterohepatic Disorders. J Med Chem. 2016; 59(19):9201-9214. DOI: 10.1021/acs.jmedchem.6b01126. View

20.

Adorini L, Trauner M . FXR agonists in NASH treatment. J Hepatol. 2023; 79(5):1317-1331. DOI: 10.1016/j.jhep.2023.07.034. View